glp-1 news nov 2025 Novo Nordisk cuts forecast amid slower sales As GLP-1 Drugs Go Mainstream,
Description
Providers Clinicians will need to prepare for increased administrative burden related to navigating prior authorization demands
Fact MR's analysis of the GLP-1 Receptor Agonist Market in South Asia, East Asia, Western Europe, North America, and India consists of country-wise assessments that include India, China, Germany, Japan, and the USA
Weight them as individual directional signals, not outcome guarantees
Das Medikament Wegovy enthlt den gleichen Wirkstoff wie Ozempic, ist aber viel hher dosiert und ist von der Europischen Arzneimittelagentur EMA als Abnehmprparat zugelassen
